Outlook Therapeutics Inc. (OTLK)
2.17
-0.12 (-5.24%)
At close: Jan 14, 2025, 3:59 PM
2.28
5.07%
Pre-market Jan 15, 2025, 05:41 AM EST
undefined% (undefined)
| Bid | 2.16 |
| Market Cap | 54.05M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -3.92 |
| PE Ratio (ttm) | -0.55 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.49 |
| Volume | 361,917 |
| Avg. Volume (20D) | 1,948,496 |
| Open | 2.29 |
| Previous Close | 2.29 |
| Day's Range | 2.11 - 2.30 |
| 52-Week Range | 0.87 - 12.85 |
| Beta | undefined |
About OTLK
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and lice...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 14, 2016
Employees 24
Stock Exchange NASDAQ
Ticker Symbol OTLK
Analyst Forecast
According to 6 analyst ratings, the average rating for OTLK stock is "Buy." The 12-month stock price forecast is $31.4, which is an increase of 1347.00% from the latest price.
Buy 83.33%
Hold 16.67%
Sell 0.00%
Next Earnings Release
Outlook Therapeutics Inc. is scheduled to release its earnings on Feb 12, 2025,
before market opens.
Analysts project revenue of $250.00K, reflecting a n/a YoY growth and earnings per share of -1.11, making a 38.75% increase YoY.
Analysts project revenue of $250.00K, reflecting a n/a YoY growth and earnings per share of -1.11, making a 38.75% increase YoY.
2 weeks ago ·
Source
+18.24%
Outlook Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
1 month ago ·
Source
-65.24%
Outlook Therapeutics shares are trading lower after the company announced it plans to resubmit the biologics license application for ONS-5010 after reporting preliminary topline results of its Norse eight clinical trial.
